bringing energy to life

Khondrion is a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease.

 

khondrion

Khondrion is a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease. Founded by Professor Jan Smeitink, a world-leader in mitochondrial medicine, the company is advancing its proprietary science through a wholly-owned clinical and preclinical small molecule pipeline of potential medicines.

COVID-19 response

Khondrion has published a scientific hypothesis on COVID-19, highlighting the potential of its lead drug candidate, sonlicromanol, currently in phase IIb development to treat a range of mitochondrial diseases, to be repurposed for the treatment of patients with severe COVID-19 disease. The company is actively searching for partners to assist in evaluating the hypothesis and the potential of bringing sonlicromanol to COVID-19 patients.

“The solution is within our reach”

Since 2012 Khondrion has been progressing a pipeline with the potential to deliver transformative medicines for patients living with mitochondrial disease.

partnering

At Khondrion, we know that working in collaboration with others is important to accelerate the development of innovative new medicines. That is why we are pursuing the newest science both within our own labs and through partnerships across an extensive clinical and academic network, exploring new avenues of science and sharing knowledge of mitochondrial disease to help develop important new treatments for patients.

Disease spotlight: Leigh disease

Simple functions such as blinking and breathing are actions that we take for granted. However, for those living with...

Khondrion is collaborating globally on its way to market

In July 2018 Khondrion was awarded €2.3M funding from the highly competitive EU Horizon 2020 SME instrument program...

Reflections on SSIEM annual symposium 2019 – Building Bridges

Reflections on SSIEM annual symposium 2019 – Building Bridges   Chief Executive Officer of Khondrion, Prof....

Khondrion granted Orphan Drug Designation for KH176 for the treatment of MIDD from European Commission

Khondrion granted Orphan Drug Designation for KH176 for the treatment of maternally inherited diabetes and deafness...

BIO-Europe 2018: Interview with Mike Ward, Chief Content Officer at Informa Pharma Insights

In November 2018, Jan Smeitink, founder and CEO of Khondrion attended the 24th Annual BIO-Europe conference in...

New Year brings new look at khondrion.com

Khondrion, the clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial...

Scientific publication in Cell Death & Disease

Results from collaborative preclinical research effort investigating Leigh disease patient cells published in Cell...

Jan Smeitink interview with Catalyze

In July 2018 Khondrion was awarded €2.3M funding from the EU Horizon 2020 Research and Innovation programme to progress clinical development of KH176, its lead pipeline asset. Prof. Dr. Jan Smeitink, Chief Executive Officer of Khondrion, talks to Catalyze®, who collaborated with Khondrion on the company’s successful funding submission, about his ambitions for Khondrion and the mitochondrial disease research his team is leading.

Publication of the KHENERGY study results

KHENERGY study provides first data on safety and efficacy of KH176 in patients with mitochondrial disease. Results from phase IIa study of innovative reduction-oxidation modulator published in Clinical Pharmacology and Therapeutics.

Khondrion awarded H2020 SME Instrument grant

Khondrion receives €2.3M funding from EU Horizon 2020 SME instrument phase 2 program.

get in touch

Whether you are a researcher, job seeker, health professional, patient or potential investor, you can contact us using this form.